TMS诱发皮层反应性特征作为抑郁症多维生物标志物:从诊断到预后的TMS-EEG荟萃分析
该研究系统检索并荟萃分析了21项单脉冲TMS-EEG研究,共纳入1,025例MDD患者和517名健康对照。结果显示负极性成分在MDD中显著增强,主要由N100驱动,且与症状严重度相关;治疗可减弱N100并提升P180,治疗诱导的负极性反应降低与临床缓解强相关,基线负极性成分可初步预测治疗反应。
要点
- MDD患者负极性成分增强,N100效应显著且与症状严重度相关
- 治疗减弱N100并提升P180,负极性反应降低与临床缓解强相关
- 基线负极性成分初步预测治疗反应,支持多维生物标志物框架
核心结论
- TMS-EEG皮层反应性特征,尤其是负极性成分及其N100亚成分,在疾病特征描述、治疗监测和结局预测中表现出一致效应,支持其作为MDD多维神经生理生物标志物的候选资格。
研究设计与样本
- 系统检索PubMed、Scopus、Ovid和Web of Science中报告MDD单脉冲TMS-EEG测量的研究,采用随机效应荟萃分析综合三个层级生物标志物验证域的证据。
- 共纳入21项研究,包含1,025例MDD患者和517名健康对照。
主要发现
- MDD中负极性成分显著增强(Hedges' g = 0.36),主要由N100驱动(g = 0.35),N100与症状严重度相关(g = 0.67)。
- 治疗减弱N100(g = -0.21)并提升P180(g = 0.52)。
- 治疗诱导的负极性反应降低与临床缓解强相关(g = 0.91),N100成分水平效应最稳健(g = 0.85)。
- 初步证据表明基线负极性成分预测治疗反应(g = 1.35)。
关键数值与推荐
- 负极性成分在MDD中增强的效应量Hedges' g = 0.36,N100亚成分g = 0.35。
- N100与症状严重度关联的效应量g = 0.67。
- 治疗对N100的效应量g = -0.21,对P180的效应量g = 0.52。
- 治疗诱导负极性反应降低与临床缓解耦合的效应量g = 0.91,N100成分g = 0.85。
- 基线负极性成分预测治疗反应的效应量g = 1.35。
临床怎么用
- TMS-EEG负极性成分及N100可作为MDD诊断、治疗监测和预后预测的候选神经生理生物标志物,有望辅助生物标志物指导的精准精神病学。
局限性
- 基线负极性成分预测治疗反应的证据为初步性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transcranial magnetic stimulation combined with electroencephalography (TMS-EEG) enables perturbation-based assessment of cortical reactivity and has emerged as a promising tool for identifying neurophysiological biomarkers in major depressive disorder (MDD). However, the literature remains fragmented, and TMS-EEG metrics have yet to be systematically integrated within a unified framework spanning diagnosis, treatment, and prognosis. METHODS: PubMed, Scopus, Ovid, and Web of Science were systematically searched for studies reporting single-pulse TMS-EEG measures in MDD. Random-effects meta-analyses were performed to synthesize evidence across three hierarchical biomarker validation domains: characterization (diagnostic discrimination and state-related symptom tracking), treatment response (intervention monitoring and clinical coupling with remission), and baseline prediction. RESULTS: Across 21 studies comprising 1,025 patients with MDD and 517 healthy controls, negative-polarity components were significantly enhanced in MDD (Hedges' g = 0.36), driven primarily by the N100 (g = 0.35), which was also associated with greater symptom severity (g = 0.67). Treatment attenuated N100 (g = -0.21) while elevating P180 (g = 0.52). Critically, treatment-induced reduction in negative-polarity responses was strongly coupled with clinical remission (g = 0.91), with the N100 showing the most robust component-level effect (g = 0.85). Preliminary evidence further indicated that baseline negative-polarity components predicted treatment response (g = 1.35). CONCLUSIONS: TMS-EEG cortical reactivity signatures, particularly negative-polarity components and their N100 subcomponent, demonstrated convergent effects across disease characterization, treatment monitoring, and outcome prediction, supporting their candidacy as multidimensional neurophysiological biomarkers for MDD with potential clinical utility in biomarker-guided precision psychiatry.
引用
- Xie JY, Zhao T, Guo L, et al. TMS-Evoked Cortical Reactivity Signatures as a Multidimensional Biomarker of Depression: A TMS-EEG Meta-Analysis from Diagnosis to Prognosis. Biol Psychiatry. 2026. PMID: 42829057. doi:10.1016/j.biopsych.2026.09.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。